share_log

榮昌生物:海外監管公告 - 2024年度向特定對象發行A股股票募集資金使用的可行性分析報告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 00:16
Summary by Moomoo AI
荣昌生物宣布计划向特定对象发行A股股票募集资金不超过255亿元人民币,用于新药研发项目。该募资计划旨在增强公司的综合竞争力和推进创新药物的研发进程。募集资金扣除发行费用后,将投资于包括RC18、RC48、RC28、RC88、RC148及RC198等产品的临床研究。公司表示,此举有助于丰富在研药物产品管线,加快产品上市注册进程,提升公司的核心竞争力。荣昌生物的新药研发项目符合国家产业政策,且公司拥有成熟的研发体系和技术优势,有望在生物创新药领域保持领先地位。本次募资预计将增强公司的资本实力,优化资产负债结构,提高抗风险能力,促进公司长期可持续发展。董事会于2024年3月29日通过了此募资计划。
荣昌生物宣布计划向特定对象发行A股股票募集资金不超过255亿元人民币,用于新药研发项目。该募资计划旨在增强公司的综合竞争力和推进创新药物的研发进程。募集资金扣除发行费用后,将投资于包括RC18、RC48、RC28、RC88、RC148及RC198等产品的临床研究。公司表示,此举有助于丰富在研药物产品管线,加快产品上市注册进程,提升公司的核心竞争力。荣昌生物的新药研发项目符合国家产业政策,且公司拥有成熟的研发体系和技术优势,有望在生物创新药领域保持领先地位。本次募资预计将增强公司的资本实力,优化资产负债结构,提高抗风险能力,促进公司长期可持续发展。董事会于2024年3月29日通过了此募资计划。
RONG CHANG BIO ANNOUNCED PLANS TO ISSUE A SHARE RAISING FUNDS NOT EXCEEDING RMB 255 TO SPECIFIC TARGETS FOR NEW DRUG R&D PROJECTS. The fundraising initiative aims to strengthen the company's combined competitiveness and advance the development process of innovative drugs. After raising funds are deducted from the release fee, it will be invested in clinical studies of products including RC18, RC48, RC28, RC88, RC148 and RC198. The company said this would help Feng-Rich's pharmaceutical product pipeline to speed up the product listing process and enhance the company's core competitiveness. RONG CHANG BIO'S NEW DRUG R&D PROJECTS ARE IN LINE WITH THE NATIONAL INDUSTRIAL POLICY AND THE COMPANY, WITH ITS PROVEN R&D SYSTEM AND TECHNOLOGICAL ADVANTAGES, IS EXPECTED TO REMAIN AT THE FOREFRONT IN THE FIELD OF BIOPHARMACEUTICAL INNOVATION. This acquisition is expected to enhance the company's capital strength, optimize its asset structure, increase risk resilience and promote long-term sustainability of the company. The Board of Directors approved this fund raising plan on March 29, 2024.
RONG CHANG BIO ANNOUNCED PLANS TO ISSUE A SHARE RAISING FUNDS NOT EXCEEDING RMB 255 TO SPECIFIC TARGETS FOR NEW DRUG R&D PROJECTS. The fundraising initiative aims to strengthen the company's combined competitiveness and advance the development process of innovative drugs. After raising funds are deducted from the release fee, it will be invested in clinical studies of products including RC18, RC48, RC28, RC88, RC148 and RC198. The company said this would help Feng-Rich's pharmaceutical product pipeline to speed up the product listing process and enhance the company's core competitiveness. RONG CHANG BIO'S NEW DRUG R&D PROJECTS ARE IN LINE WITH THE NATIONAL INDUSTRIAL POLICY AND THE COMPANY, WITH ITS PROVEN R&D SYSTEM AND TECHNOLOGICAL ADVANTAGES, IS EXPECTED TO REMAIN AT THE FOREFRONT IN THE FIELD OF BIOPHARMACEUTICAL INNOVATION. This acquisition is expected to enhance the company's capital strength, optimize its asset structure, increase risk resilience and promote long-term sustainability of the company. The Board of Directors approved this fund raising plan on March 29, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more